This study looks at a new medicine called zilovertamab vedotin. It will be given with standard treatment to see if it helps people with diffuse large B-cell lymphoma live longer without the cancer growing or spreading. The main goal is to find out if this combination is better than the standard treatment alone.
The trial ID is NCT06717347. It is a Phase 3 study, which means the trial is looking at how well the treatment works and how safe it is. The study is regulated by the FDA and aims to include about 1,046 participants.
Who can join
Adults aged 18 and older can join this study. It is open to both men and women who have been diagnosed with diffuse large B-cell lymphoma and have not received any treatment yet. Some health conditions may prevent people from joining, but the trial team will confirm eligibility.
Condition
Diffuse Large B-Cell Lymphoma
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be placed into two groups by chance. One group will receive zilovertamab vedotin along with rituximab, cyclophosphamide, doxorubicin, and prednisone. The other group will receive rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone. Treatment lasts for about four months, with regular visits for infusions and check-ups.
Where
This trial is enrolling at 42 locations. Recruiting sites are listed first.
American Oncology Partners, P.A. ( Site 0185)
Bethesda, Maryland
Recruiting
Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167)
Professor and transplant specialist, UC Davis. Treats leukemia, lymphoma and multiple myeloma. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.
Associate Professor of Radiation Oncology at the University of Vermont Larner College of Medicine and practices. Treats lung cancer, breast cancer, anal cancer and bone cancer. Also treats brain tumor, lymphoma and pancreatic cancer.